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Mucosal melanoma — clinical 
presentation and treatment based  
on a case series
ABSTRACT
Melanoma is malignant disease originating from melanocytes (pigment cells that occur mainly in the skin and 
constitute a type of defence from ultraviolet radiation). Melanocytes also occur outside of the skin (among oth-
ers — in the eyeball, the mucosal lining of the digestive tract from the oral cavity to the anus, the nasal cavity 
and the paranasal sinuses, and the urinary and reproductive tracts). Many known cases of melanoma in the 
aforementioned locations exist.
The main factor responsible for the development of skin melanoma is ultraviolet radiation. In the case of mucosal 
melanoma, aetiological factors are still unknown. Mucosal melanoma most often develops in places that are hid-
den and not accessible through standard testing. Therefore, the disease develops without any signs for a long 
period of time before the proper diagnosis is established (usually at a disseminated stage, at a point where no 
successful localised treatment can be applied), which, in combination with a more aggressive course in com-
parison to more typical locations (the skin, the eyeball), a different sensitivity to systemic treatment (usually the 
lack of a mutation in the BRAF gene), and the lack of a separate standardised treatment procedure, is the cause 
of worse outcomes and poor prognosis.
Mucosal melanomas occur very rarely (about 1.5 % of all melanomas); however, the knowledge that a melanoma 
may also develop in locations that are often omitted during routine examination (the anus, the oral cavity, the 
urogenital region), may increase the chances of early diagnosis and attaining better treatment results.
In this paper, a brief description of the characteristics of mucosal melanoma is presented, along with a pres-
entation of the most common locations, symptoms, diagnostic possibilities, and available treatment (including 
immunotherapy). Based on the available literature and personal experience, several cases of patients treated in 
the Institute of Oncology are described.
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Introduction
Melanocytes — cells that produce melanin — occur 
in the basal layer of the skin, the uvea, the arachnoid ma-
ter, and pia mater, but can also be found in the mucosal 
lining of the airways, digestive and urogenital tracts. Due 
to the presence of melanocytes mucosal melanoma may 
develop in all of the aforementioned locations. Mucosal 
melanoma is very rare, constituting only 0.03% of all 
neoplasms, and about 1.5% of all cases of melanoma 
[1–3]. While melanoma can develop on the surface of 
all mucosa, the majority occur in the mucosa of the head 
and neck (31–55%), the anus and rectum (17–24%), 
and the vulva and vagina (18–40%); the less common 
locations are the mucosal lining of the pharynx, larynx, 
urinary tract, uterine cervix, oesophagus, and gallblad-
der [3, 4]. It is noted, however, that a certain fraction of 
mucosal melanoma patients may be the ones who could 
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not have a primary lesion identified, and individuals 
with a skin melanoma that has undergone regression.
The incidence of skin melanoma has been rising 
— also in Poland — in the past two decades, while 
remaining stable in the case of mucosal melanoma [5, 
6]. The risk of developing mucosal melanoma rises with 
age, and most of the patients are over 60 years of age 
(median age of diagnosis is 70 years). The incidence of 
mucosal melanoma is only twice as high in Caucasian 
individuals as in the African American population, while 
in the case of skin melanoma, this ratio is 16 to 1 [7]. 
Skin melanoma occurs more often in men than it does 
in women, and the frequency of occurrence of mucosal 
melanoma is 87% higher in women than it is in men, 
which is probably related to a greater percentage of 
melanoma of the reproductive organs in women [3].
Melanomas of the mucosa are characterised by 
a more aggressive course, and patients have a worse 
prognosis when compared to other types of melanoma 
(skin and ocular melanoma). The overall five-year 
survival rate for skin melanoma amounts to 80%, while 
for mucosal melanoma it only reaches 25%. The poorer 
treatment outcomes and shorter survival rate may be 
related to a generally more advanced disease upon dia-
gnosis, anatomical factors that hinder complete resec-
tion and ample lymphatic drainage from the surfaces of 
mucosa, and other genetic and biological factors. The 
lack of early symptoms, and a sneaky evolution in lo-
cations that are typically inaccessible to examination, 
cause mucosal melanomas to be diagnosed late, at 
a time when the disease is very advanced. Amelanotic 
forms, which are not rare in the case of mucosal mela-
nomas, additionally make the diagnosis more difficult. 
What is interesting, besides a lower survival rate since 
diagnosis, mucosal melanoma patients also have lower 
survival rates regardless of the stage of the disease, 
which especially pertains to people with metastases 
(M1 parameter) [3].
In mucosal melanoma patients, metastases are most 
often observed in the lungs (54%), liver (35%), and 
bones (25%) — the arrangement of metastasis loca-
tions differs from the case of skin melanoma, where 
metastases are found mainly in the skin (13–38%), lungs 
(18–36%), and lymph nodes (5–34%) [8].
Currently, there are no known risk factors for the 
development of mucosal melanoma. No relationship 
with ultraviolet radiation has been proven, and viral 
aetiology has also been excluded (within it — a relation-
ship with SMV, EBV, HPV, or HSV) [9–11]. However, 
a greater percentage of individuals with history of 
formaldehyde exposure develop mucosal melanoma, 
as well as those who smoke tobacco (melanoma of the 
oral cavity), which may indicate the mutagenic effect of 
these two factors as well as an influence on the develop-
ment of the illness [3, 7, 12, 13].
The types of molecular disorders responsible for the 
development of skin and mucosal melanoma differ from 
each other. In the case of skin melanoma, mutations 
in the BRAF gene occur in about half of the patients, 
while in the case of mucosal melanoma this mutation 
was identified in only a small number of patients (3–11% 
mucosal melanomas have the BRAF gene mutation, and 
another 5–14% have a mutation in the NRAS gene). 
However, the percentage of mutations occurring in the 
gene responsible for coding the receptor for tyrosine 
kinase (KIT) is greater. This mutation was identified 
in around 39% of mucosal melanoma patients, and 
20% of rectal melanomas have deactivating mutations 
in the NF1 gene [14–16]. Mucosal melanomas contain 
an average of 8193 point mutations per tumour, which 
is over 10 times fewer mutations than skin melanoma 
(86,495 changes). While gene amplifications are rare 
in skin melanoma, they are present in about 85% of 
mucosal melanomas. Furthermore, the mucosal mela-
noma has an average of 3.7 more structural variants 
when compared to the skin melanoma, and the cause 
of this increased chromosomal instability has not yet 
been explained [3].
Due to the rarity of its occurrence, the mucosal 
melanoma’s aetiopathogenesis and clinical course are 
poorly known, and there is a lack of separate, specific 
recommendations pertaining to treatment, although the 
ESMO (European Society of Medical Oncology) and 
NCCN (National Comprehensive Cancer Network) rec-
ommendations point out the importance of radiotherapy 
in this group of patients [17].
In the process of diagnosing mucosal melanomas, it 
is crucial to rule out metastatic disease from a different 
location (primary lesion in the skin or eyeball), which 
means a thorough examination of the entire skin and 
mucosa, including a dental, ophthalmological, rectal, 
and gynaecological examination.
The main treatment method for patients who de-
velop mucosal melanoma is surgical treatment. Unfor-
tunately, due to its sneaky evolution and late diagnosis 
at a usually advanced stage, the results of surgical treat-
ment are not satisfactory. A further limit to the preci-
sion of a resection is the location, which significantly 
defines the attainable surgical margin (the maxillary 
sinus, the rectal canal). In the treatment of mucosal 
melanomas, a relatively wide scope of resections was 
applied (i.e. abdominoperineal rectal resection in the 
case of anal cancer); however, long-term analyses show 
that long-term effects are not better when compared to 
a local excision with a wide margin, while the quality 
of life of the former patients is incomparably worse. 
Because of this, a wide local excision of the primary le-
sion is currently recommended, regardless of location, 
instead of a more extensive and debilitating operation. 
Radiotherapy improves localised control of the lesion 
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but does not affect the improvement of overall survival 
(OS). Currently there is no effective systemic treatment 
for this group of patients, and the results of treatment 
for mucosal melanoma in comparison with skin mela-




A 56-year-old female came to the regional cen-
tre in May of 2017 due to swelling of the right side 
of her face. The patient was hospitalised in August 
2017 in the department of otorhinolaryngology (ORL) 
in a voivodeship-level hospital for diagnostic purposes 
pertaining a tumour of the right nasal cavity — a biopsy 
was taken from the right maxillary sinus, and a partial 
resection of the lesion (R1) was performed; the patho-
logy result established a diagnosis of melanoma. During 
another hospitalisation in a regional ORL department, 
a computed tomography (CT) imaging of the sinuses 
was performed, and showed an abnormal mass within 
the entire right maxillary and frontal sinuses, the right 
ethmoid sinus, and the right chamber of the sphenoid 
sinus, with an occlusion of the outflow tracts. The masses 
filled the nasal cavity on the right, with an infiltration of 
the right levator anguli oris, and a partial destruction of 
the cavity’s medial wall the ethmoid bone. After several 
weeks, the patient underwent her first consultation 
at Centrum Onkologii — Instytut (COI) in Warsaw, 
and during the diagnostic process no mutation in the 
V600 codon of the BRAF gene was detected. 
In December of 2017, immunotherapy (nivolumab 
— drug program) was initiated. As a continuation of 
local treatment, due to persistent bleeding from the 
lesion, the right external carotid artery was ligated, 
and a total maxillectomy with orbital exenteration was 
performed (R1 resection — February 2018). After 
surgery, the patient underwent adjuvant radiotherapy 
(May 2018) on the postoperative site up to a total dose 
of 5500 cGy/t. Immunotherapy was continued. In a con-
trol CT scan in September 2018, a suspicious lesion in 
the postoperative area was described, as well as lesions 
in the bronchi. The small tumour in the vicinity of the 
zygomatic bone in the postoperative lesions had a dia-
meter of approximately 11 mm (previously 19 × 14 mm) 
and was not enhanced by contrast. The patient had 
a thin-needle biopsy of the lesion performed three 
times; no malignant cells were discovered. A 15 × 9 mm 
focal lesion on the right side of the trachea appeared, 
as well as a 6 mm lesion in the proximal section of the 
left bronchus, and an 11 mm lesion in the lower right 
lobar bronchus. 
In March of 2018 the patient had a bronchoscopy 
with tissue sampling for the purpose of pathological 
testing — melanoma cells were detected in the sample 
tissue. The patient was referred to radiation oncologist 
to be qualified for brachytherapy. The patient remains in 
an overall adequate state. Due to the extensive surgery in 
the maxillofacial region, she has problems with speech. 
Laboratory tests show no significant abnormalities 
besides normocytic anaemia. The patient continues im-
munotherapy with no significant toxicity and no further 
disease progression.
Case 2
A 66-year-old male presented to the regional centre 
complaining of abnormal defecation pattern. Magnetic 
resonance imaging (MRI) of the pelvis performed in 
October 2017 described a cauliflower-like tumour mass 
in the lesser pelvic cavity sized 85 × 100 mm infiltrating 
subcutaneous tissue of the coccygeal region. A cutting 
needle biopsy (CNB) of the anal tumour was performed, 
showing a melanoma (melanoma malignum Melan A+, 
S-100 –/+). During the diagnostic process at COI, no 
distant metastases were described in the imaging, and 
a lack of the BRAF B600 mutation was confirmed. Im-
munotherapy (pembrolizumab) was given within a drug 
program. In February 2018 the patient underwent ra-
diotherapy of the rectum and lymph nodes with a dose 
up to 2500 cGy. In the most recent control CT (March 
of 2018), a tumourous mass was apparent, encompass-
ing the anus and prostate, with stable dimensions and 
constant, transverse infiltration with dimensions of 
61 × 43 mm, as well as lymph nodes of stable dimensions 
(a 12 mm lymph node by the right external iliac vessels, 
a 14 mm node by the right internal iliac vessels, and 
a node by the left external iliac vessels with 10 mm in the 
short axis). No metastases have been found so far. The 
patient remains in good general condition, with pain well 
controlled with analgesics. The disease has been stable 
for a year, and the immunotherapy has had the side 
effect of joint pain and skin pruritus assessed as level 1.
Case 3
A 65-year-old female presented to her regional 
gynaecology clinic due to vaginal bleeding. History in-
cluded hypertension, asthma, and 20 years of cigarette 
smoking. In July 2018 an in-hospital biopsy of a vaginal 
lump was performed, and an initial diagnosis of a vagi-
nal polyp was made. However, the results of pathology 
testing contained the diagnosis of a non-pigmented 
mucosal melanoma [CK(–), S100(+), HMB45(+)]. 
In a CT scan of the thorax, abdomen, and pelvis per-
formed in 2018 no metastases were found (including 
any metastases to the lesser pelvis). In September 2018, 
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the patient underwent her first consultation at COI. 
Gynaecological examination showed an abnormal le-
sion about 2 cm in diameter in the vaginal wall, near 
the urethral opening, with a suspicion of infiltration 
of its distal part. In a CT of the thorax, abdomen, and 
pelvis performed in September 2018, the uterine body 
was smooth, free, ante-flexed, and with no pathological 
mass within the projection of the adnexa. Additionally, 
clinical examination revealed enlarged right inguinal 
lymph nodes. 
Then, in October 2018, the patient underwent an 
excision of the exophytic lesion along with the distal 
part of the urethra (about 1 cm). Pathology results 
revealed infiltration of the mucosa and muscle layer of 
the urethra. The melanoma was 20% necrotic, and its 
greatest dimension was about 1.4 cm. The infiltration 
encompassed the mucosa and muscle layer of an ulcer-
ated urethral wall. Neoplastic invasion of vessels was 
noted. No neoplastic invasion of the nerve fibres was 
revealed. Malignant infiltration was present in the front 
margin (R1), while other margins were free. The patient 
was referred for qualification for immunotherapy with 
immune checkpoint inhibitors and is currently being 
qualified for a clinical study.
Discussion
Mucosal melanoma immunotherapy
Current data on the effectiveness of checkpoint 
inhibitors is limited in the case of patients with mu-
cosal melanoma. Several institutions have published 
analyses of patients with the diagnosis of mucosal 
melanoma, who were undergoing immunotherapy. 
The percentage of objective responses was, however, 
low (11.8%), although permanent responses were 
noted (including a permanent response to ipilimumab 
used as first-line treatment, and pembrolizumab as 
the second line). With a median observation time of 
10.1 months, the median progression-free survival (PFS) 
and overall survival (OS) were 3.1 and 8.8 months, 
respectively. Nevertheless, amongst the scant number 
of patients who achieved objective responses, survival 
exceeding 56 months was observed [19]. In a compara-
tive analysis of anti-PD-1 and anti-CTLA-4 treatment, 
a higher effectiveness of anti-PD-1 drugs was shown. In 
a French analysis, a total of 110 patients were included 
in the study. The median PFS was somewhat better in 
the group that received anti-PD1 drugs, when compared 
to the anti-CTLA4 group (3.9 months, compared with 
2.9 months, P = 0.025) [20]. Single series of cases from 
other institutions revealed a complete lack of objective 
responses to anti-PD-1 treatment [21], although in other 
reports, the objective responses were seen in 23% of 
patients suffering from mucosal melanoma (median 
PFS — 3.9 months) [22].
The results of immune checkpoint inhibitor-based 
immunotherapy as monotherapy in patients with 
mucosal melanoma seem to be only somewhat better 
than known outcomes of chemotherapy. In the largest 
analysis of 95 patients undergoing chemotherapy due 
to mucosal melanomas, the median OS amounted to 
12.1 months with the response rate of 26.3%. The re-
sults of this analysis were comparable to historical case 
series, and no statistical difference was revealed in the 
scope of responses between skin melanoma and mucosal 
melanoma (30% and 20%, P = 0.206); similarly, no dif-
ference was shown between patients of Caucasian and 
African origin (20% and 36%, respectively), and the 
median PFS in subsequent patient series amounted to 
3 to 10 months [23].
The earliest results of immunotherapy are those 
from ipilimumab treatment (an anti-CTLA-4 drug). 
A retrospective analysis of 33 patients, most of whom 
were treated earlier at least once, showed a complete 
response in one patient, a partial response also in one 
patient, and six patients with stable disease according 
to the iRECIST immunological response criteria. The 
median OS from the time of the first dose of ipilimumab 
was 6.4 months (range: 1.8–26.7 months) [24]. 
Another analysis of 71 patients with metastatic mu-
cosal melanoma treated with ipilimumab in an expanded 
access program in Italy showed an objective responses 
in 12% of patients, and a disease control rate of 36%, 
with a median observation time of 21.8 months. The 
average PFS in this patient group was 4.3 months, and 
the median OS reached 6.4 months [25]. 
In another study, which included patients with 
mucosal melanoma, seven patients were assessed, of 
whom only four completed the induction phase of four 
cycles of ipilimumab. One-year OS in this study was 14% 
and all patients with mucosal melanoma died within 
24 months after receiving the first dose of ipilimumab. 
Of the patients studied, one achieved partial response, 
and two achieved stabilisation of disease [26]. The 
median OS, which amounted to 10.1 and 11.2 months, 
achieved by patients in the drug registration studies 
for ipilimumab, seems to be longer in comparison with 
the median OS found in smaller studies (6.4, 6.7, and 
5.8 months, respectively) [24, 25, 27]. Ipilimumab treat-
ment in conjunction with radiotherapy was also used in 
neoadjuvant treatment at the Memorial Sloan Ketter-
ing Cancer Centre. After applying such treatment, an 
R0 resection proved to be possible, as well as a single 
pathological response [28]. 
It has been shown that monoclonal antibodies aimed 
at PD-1 or PD-L1 are more effective, when compared 
with ipilimumab, in the treatment of melanoma patients, 
which suggested greater effectiveness in the treatment of 
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mucosal melanoma. The effectiveness of anti-PD1 an-
tibodies in mucosal melanoma patients has so far been 
fairly well documented. The effectiveness of pembroli-
zumab treatment was tested based on data from regis-
tration studies. Of the patients treated in the studies of 
KEYNOTE-001 (NCT01295827), -002 (NCT01704287), 
and -006 (NCT01866319), 84 (5%) were treated for a di-
agnosis of mucosal melanoma. Fifty-one of 84 patients 
did not receive earlier ipilimumab immunotherapy. In 
patients with a diagnosis of mucosal melanoma, the ob-
jective response rate was 19%, and the median response 
duration was 27.6 months. Responses were achieved in 
22% of patients not treated with ipilimumab, and in 15% 
of those who were treated with this drug as the first line 
of treatment. The average PFS amounted to 2.8 months, 
and the median OS reached 11.3 months [29]. 
The first interesting case of response to nivolumab 
immunotherapy in a patient with mucosal melanoma was 
reported in the CheckMate 066 study. A case of a pa-
tient with an untreated metastatic mucosal melanoma 
was described, with high initial lactate dehydrogenase 
(LDH) activity (seven-times the upper reference limit). 
The patient was included into a clinical trial, achieving 
partial response and subsequently permanent total re-
sponse. LDH activity decreased significantly within two 
months of the beginning of treatment (at which time the 
patient achieved partial response) and was maintained 
at a low level throughout the observation period. The 
patient suffered only mild side effects (levels 1–2: vitiligo 
and skin rash). 
The research team suggested that nivolumab treat-
ment may be considered in mucosal melanoma patients 
with high LDH activity [30]. In order to evaluate the 
effectiveness of nivolumab in patients with a diagnosis 
of mucosal melanoma, a phase III study analysis was 
conducted. In 86 patients with mucosal melanoma, 
who were treated in clinical trials, the percentage of 
objective responses amounted to 23.3% for nivolumab 
as monotherapy, and 37.1% in the group treated with 
nivolumab combined with ipilimumab. The average PFS 
was 3.0 months for patients treated with nivolumab mon-
otherapy, and 5.9 months for those receiving nivolumab 
plus ipilimumab, which suggests that nivolumab in com-
bination with ipilimumab has greater effectiveness than 
any one of these drugs given as monotherapy [31]. An in-
teresting fact is that the expression of PD-L1 in skin and 
mucosal melanoma patients was different; fewer patients 
with mucosal melanoma were PD-L1 positive (17.4% 
and 28.6% with a 5% PD-L1 expression in the group re-
ceiving nivolumab monotherapy and the group receiving 
combination therapy, respectively). In skin melanoma 
patients, this percentage was 34.3% and 36.8%, with 5% 
having PD-L1 expression in monotherapy and combined 
therapy. The rates of treatment response were higher in 
the group of mucosal melanoma patients with a greater 
than 5% PD-L1 expression, although responses were still 
observed in the < 5% PD-L1 expression group, both in 
those receiving monotherapy as well as nivolumab with 
ipilimumab [31].
Sequential treatment in mucosal melanoma patients 
was evaluated in Japanese institutions. Out of 60 pa-
tients, only 38% finished treatment with four doses of 
ipilimumab. Objective response was achieved in the 
second-line of immunotherapy in 3.6% of patients. Side 
effects associated with immunotherapy occurred in 78% 
of the patients, and 70% of them had level 3 and 4 side 
effects, where 31% of patients had two or more side 
effects. A time less than 28 days between the first- and 
second-lines of treatment correlated with the develop-
ment of immunological complications [32].
New treatment methods for mucosal melanoma 
include combinations of immunotherapies, or immu-
notherapies and local therapies. Single examples of ef-
fective peritumoral injections with b-interferon (IFN-b) 
and interleukin 2 (IL-2) in combination with nivolumab 
have been reported [33, 34]. Targeted treatment, includ-
ing that with the use of BRAF/MEK or KIT inhibitors 
(imatinib), may be considered in the carriers of adequate 
mutations [35]. 
Mucosal melanoma of the oral cavity 
The diagnostic criteria for primary oral cavity mu-
cosal melanoma include the appearance of a clinical 
and microscopic presentation of a neoplasm in the 
mucosa of the oral cavity, the presence of melanocytic 
proliferative nests in the mucosa of the oral cavity, and 
failure to establish a different primary location [36, 37]. 
Considering the fact that 1/3 of oral mucosal melanoma 
cases develop from previously existing melanotic lesions, 
every abnormalities in the area are worth assessing, and 
an excisional biopsy should be performed in doubtful 
situations. Excision still remains the main treatment 
method, which is combined with adjuvant radiotherapy, 
and immuno/chemotherapy. These melanomas are 
characterised by several features:
 — they usually develop de novo; however, in 1/3 of 
cases they develop from a previous melanotic le-
sion [38, 39]; 
 — initially the tumour is usually symptom-less, with the 
appearance of a flat mark or slightly raised, irregular 
melanotic lesion [40, 41];
 — at a later stage of the disease, swelling, ulceration, 
bleeding, and pain appear, with the possibility of 
dental mobility, and the primary lesion becomes 
raised and lumpy
 — the primary lesion may develop satellite lesions [42];
 — amelanotic types of melanoma in the oral cavity are 
not rare, they usually delay diagnosis and treatment, 
and consequently have a worse prognosis [43];
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 — in about 25% of patients, metastases to the regional 
lymph nodes are present at the time of diagnosis 
[40, 41]; 
 — 5-year survival rate is poor, at 12.3–16.6%, with 
a median survival of 2 years [38, 44]. 
Melanoma of the colon and anal mucosa
Melanoma of the anorectal region is often initially 
misdiagnosed as haemorrhoids, which significantly 
delays the proper diagnosis, and worsens patient prog-
nosis. Most melanomas in this area are localised 
within the reach of the per rectum examination, which, 
in most cases, enables them to recognise any abnormali-
ties. Unfortunately, even 1/3 of anorectal melanomas 
are amelanotic, and a biopsy of the lesion is key in the 
diagnosis of a suspicious lesion. The Miles operation (an 
abdominoperineal resection in anorectal melanoma) 
was considered the standard treatment for melanoma 
in this location. Currently, it seems that wide local exci-
sion will take its place. While a less invasive treatment, 
it gives similar long-term results. A wide local excision 
provides more local remissions, but does not affect 
the OS rate, and adjuvant radiotherapy improves local 
maintenance but does not affect survival [45–48]. The 
five-year survival rate for locally advanced disease is 
26.7%, and 9.8% for disease with metastases to lymph 
nodes, with a median OS of 24 months and 17 months, 
respectively. In patients with metastases to the lymph 
nodes, a selective lymphadenectomy is recommended 
[49]. Additionally, the melanoma in this particular area: 
 — is the most common primary site of melanoma of 
the digestive tract mucosa [50];
 — is the third most common location after skin and 
ocular melanoma [50];
 — melanoma of the ano-rectal region occurs most 
often in patients 65–70 years of age, with women in 
the lead [45, 49];
 — the primal lesion may occur in the anal canal, the 
rectum, or in both of these places;
 — in most cases it occurs within 6 cm of the anal 
verge [51];
 — the most common symptoms are: anal bleeding, pain 
and discomfort in the anal region, as well as anal 
prolapse of the tumour [2];
 — amelanotic tumours constitute about 30% of cases [2];
 — non-specific symptomatology, polymorphism of the 
primary site often influence a wrong primary diag-
nosis — this pertains to about 2/3 of patients (most 
often diagnosed as haemorrhoids, adenocarcinoma, 
polyps, rectal cancer) [46, 51];
 — at time of diagnosis, 30% of patients already has 
metastases (regional or distant) [45, 52];
 — overall survival remains poor (20% after 5 years 
with median survival of 14–20 months) [18, 51, 53].
Melanoma of the genitourinary system 
Genito-urinary melanomas are rare and can develop 
from the mucosa of any part of the genitourinary tract 
(the vulva, vagina, cervix, urethra, bladder). Women are 
affected more often. Following features are characteri-
stic of these melanomas:
 — melanoma developing from the female genital tract 
constitutes 18% of all cases of mucosal melanoma 
and most often pertains to the vulva (76.7%) and 
vagina (19.8%) [2, 39];
 — vulvar melanoma usually affects women around 
68 years of age, mainly Caucasian (90%), and devel-
ops around the clitoris and labia majora [54];
 — the main symptoms of vulvar melanoma include: 
bleeding, lumpy lesions or a thickening on the vulva, 
pruritus, pain, inflammation, pain during urination, 
discharge [55, 56];
 — the main treatment method for vulvar melanoma 
is surgical excision, and, similarly to the previously 
described forms of mucosal melanoma, a more con-
serving surgery is recommended due to a lack of 
difference in survival [57].
Melanoma of the airways 
Melanomas of the airway mucosa are most often 
located in the nasal cavity and the paranasal sinuses, 
and the tumour can also be amelanotic. They are char-
acterised with the following features:
 — the most common symptoms include: unilateral 
obstruction of the nasal cavity, pathological tissue 
mass, nasal bleeding [58];
 — at a more advances stage: pain, facial deformation, 
less often exophthalmos double vision;
 — macroscopically the tumour has the appearance of 
a multi-shaped brown or black mass, often ulcerated;
 — 5-year survival rate for melanoma of the nasal cav-
ity is 31%, and 0% for melanoma of the maxillary 
sinus [44].
Summary
Awareness of the possibility for melanoma occur-
ing in places that are available for examination (i.e. the 
oral cavity, urogenital region, anal canal) allows for 
a diagnosis of the disease at an early stage, which gives 
an opportunity for better treatment outcomes. A diag-
nosis of the disease at a point of dissemination, which 
is unfortunately when mucosal melanoma is most fre-
quently diagnosed, is still predictive of a very unfavour-
able outcome, and the results of systemic treatment are 
poor. The presented cases show that immunotherapy 
can be an effective method of treatment for patients 
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with metastatic mucosal melanoma, although gener-
ally mucosal melanomas have poorer outcomes when 
compared with skin melanoma (shorter PFS and OS) 
when it comes to treatment with nivolumab, or pem-
brolizumab in monotherapy. Some patients may benefit 
significantly from immunotherapy, especially combina-
tion of anti-PD-1 with anti-CTLA-4, but currently we 
have no legitimate predictive biomarkers for patient 
selection. Despite many effective treatment options for 
skin melanoma, data on the treatment of melanomas 
in other locations are limited, and clinical decisions are 
often made based on retrospective data and reports 
from other institutions, including case series analyses.
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